Medicament for preventing in-stent restenosis after vascular intervention and preparation method thereof

A technology of restenosis and drugs, applied in the field of pharmaceuticals, can solve problems such as renal damage and effect on curative effect

Inactive Publication Date: 2008-10-01
宫丽鸿
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Purpose of the invention: the present invention provides a drug for preventing postoperative restenosis after coronary heart disease intervention and its preparation method, which solves the problem that the postoperative restenosis affecting the curative effect in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for preventing in-stent restenosis after vascular intervention and preparation method thereof
  • Medicament for preventing in-stent restenosis after vascular intervention and preparation method thereof
  • Medicament for preventing in-stent restenosis after vascular intervention and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] A medicine for preventing restenosis after interventional coronary heart disease. The medicine is used as a medicine for treating restenosis after stent intervention for coronary heart disease. 10-20: cinnamon 10-20: peach kernel 10-20: leeches 20-30: honeysuckle 15-25.

[0020] a. Soak 30g of rhubarb, 15g of Glauber’s salt, 15g of licorice, 15g of cinnamon, 15g of peach kernel, 25g of leech, and 20g of honeysuckle in water for 0.5 hours;

[0021] b. Heat the water to boiling with strong fire, then decoct with slow fire and water for 1 hour, and control the temperature of slow fire heating at 75-85°C;

[0022] c. After filtering through gauze, concentrate in a 100°C water bath to 100mL to obtain a finished product, seal and store in a refrigerator at 3-6°C.

[0023] The concoction contains active ingredients with therapeutic effects. If the temperature is too high, the therapeutic effect will be affected. Therefore, the temperature must be controlled well. Therefore, a...

Embodiment 2

[0025] A drug for preventing restenosis after interventional coronary heart disease, the drug is carried out according to the following steps:

[0026] a. Soak 25g of rhubarb, 20g of Glauber’s salt, 20g of licorice, 20g of cinnamon, 20g of peach kernel, 25g of leech, and 20g of honeysuckle in water for half an hour;

[0027] b. First heat the water to boiling with a strong fire, then fry it with a slow fire for 2 hours. The temperature of the slow fire heating is controlled at 75-85°C; then pour out the concoction, add water and continue to decoct. Merge; the reason for decocting three times is because the medicinal components in the raw materials can be extracted more effectively through repeated decoction.

[0028] c. After filtering with gauze, concentrate in a 100°C water bath to 100mL, seal and store in a refrigerator at 3-6°C. .

Embodiment 3

[0030] A drug for preventing restenosis after interventional coronary heart disease, the drug is carried out according to the following steps:

[0031] a. Soak 35g of rhubarb, 20g of Glauber’s salt, 20g of licorice, 15g of cinnamon, 15g of peach kernel, 20g of leech, and 15g of honeysuckle in water for half an hour;

[0032] b. Heat the water to boiling with a strong fire and then fry it with a slow fire for 3 hours. The temperature of the slow fire heating is controlled at 75-85°C, then pour out the concoction, add 110g of water to continue decocting, and decoct 3 times in total. The juice is combined; the reason for decocting three times is because the active ingredients of the medicine can be more fully utilized after repeated decoction;

[0033] c. After filtering with gauze, concentrate in a water bath at 100°C to 100mL, and store in a refrigerator at 6°C.

[0034] In order to verify the effect of the present invention, the experimental method and the results realized ar...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a medicine for preventing postoperative restenosis of coronary artery after percutaneous coronary intervention (PCI) and a preparation method, which pertain to the pharmacy field and are characterized in that: the medicine is prepared from the raw materials by decocting with water according to the following weight ratio: 25 to 35 of Chinese rhubarb: 10 to 20 of mirabilite: 10 to 20 of liquorice: 10 to 20 of cinnamon: 10 to 20 of peach kernel: 20 to 30 of leech: 15 to 25 of honeysuckle. The medicine of the invention solves the problems that the postoperative restenosis of coronary artery appearing in percutaneous coronary intervention (PCI) influences the curative effects and the conventional western medicines cause damage to liver function and renal function, massive hemorrhage, etc. when being used for preventing postoperative restenosis of coronary artery.

Description

Technical field: [0001] The invention belongs to the field of pharmacy, and particularly relates to a medicine for treating coronary artery restenosis complications after stent intervention for treating coronary heart disease and a preparation method thereof. Background technique: [0002] Coronary heart disease is one of the most important diseases that endanger human life. At present, interventional therapy has been actively carried out in the cardiovascular field, and the coronary interventional therapy (PCI) based on percutaneous transluminal coronary angioplasty (PTCA) has developed rapidly and has become a relatively mature treatment for coronary artery revascularization. The means have successfully saved the lives of many patients. The rate of restenosis (RS) after intervention has dropped from 20% to 30% in the era of percutaneous transluminal coronary angioplasty (PTCA) to 5% to 8% in the current era of drug stents [1] , but postoperative restenosis (RS) is still ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/73A61P9/10A61K33/04A61K35/62
Inventor 宫丽鸿
Owner 宫丽鸿
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap